September brought with it six-month trial outcomes, funding updates, and all-time lows, with Merit Medical presenting six-month results from the Wrapsody WAVE trial, Venova Medical and Invizius both announcing new funding updates, and new research recently published in the Journal of the American Medical Association (JAMA) indicating a record-low risk of death for kidney donors.
Merit Medical announced today plans to release findings from its WAVE study. A pivotal, international, multicentre trial, the WAVE study examines the safety and efficacy of Merit’s Wrapsody cell-impermeable endoprosthesis for treatment of stenosis in the venous outflow circuit.
XS Innovations announced the successful closure of a EUR 1.1 million seed funding round. It states in a press release that this investment will accelerate the development of XS Innovations’ “revolutionary” Dynamic AVF, a state-of-the-art vascular access device designed to address the prevalent complications associated with haemodialysis.
Merit Medical announced positive six-month findings from the randomised arteriovenous (AV) fistula arm of its Wrapsody Arteriovenous Access Efficacy (WAVE) pivotal trial.
From how he started his career in interventional radiology (IR), to his work with the Society of Interventional Radiology (SIR), professor emeritus at UT Southwestern Medical Center, Bart Dolmatch (Mountain View, USA), speaks to Renal Interventions about his career.
Venova Medical announced the initial closing of a US$30M Series B funding round. Catalyst Health Ventures and a leading medical device company co-led the financing, with participation from ShangBay Capital, Mirae Asset Capital, KOFA Healthcare, Cadence Healthcare Ventures, Aphelion Capital and other new and existing investors.
A new research letter published last week in the Journal of the American Medical Association (JAMA) shows that risk of death for people who donate a kidney for transplantation—which was already low a decade ago—has dropped by more than half since then.
Invizius has just announced that it has raised £950,000 in a funding round led by Mercia Ventures and supported by Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital and Scottish Enterprise.
In a video interview, Matteo Tozzi (Varese, Italy) recently spoke to Renal Interventions about the role of drug-coated balloons (DCBs) in vascular access.
This video is sponsored by Cardionovum®.
Akebia Therapeutics and US Renal Care (USRC) announced plans to begin a collaborative clinical trial of the recently approved Vafseo (vadadustat). The first patient in this trial is expected to be enrolled this year.
The National Kidney Foundation (NKF) launched NKF Patient Journey: Chronic Kidney Disease, a new interactive, online learning tool that it hopes will aid people living with chronic kidney disease (CKD) in learning more about the condition in a personalised way.
